1. AB0017 Association study of genetic risk variants for psoriasis in a large cohort of psoriatic arthritis, psoriasis and controls of the spanish population and association with relevant clinical subphenotypes. (23rd January 2014) Authors: Cañete, J.D.; Hernanz, J.M.; Fonseca, E.; Ferrandiz, C.; Unamuno, P.; Puig, L.; Fernandez-Sueiro, J.L.; Sanmartí, R.; Rodriguez, J.; Gratacόs, J.; Dauden, E.; Sánchez-Carazo, J.L.; Lόpez-Estebaranz, J.L.; Moreno, D.; Queirό, R.; Ferrandiz, C.; Torre-Alonso, J.C.; Pérez-Venegas, J.J.; Vanaclocha, ... Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 638 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Comparison of ixekizumab with ustekinumab in moderate‐to‐severe psoriasis: 24‐week results from IXORA‐S, a phase III study. (19th July 2017) Authors: Reich, K.; Pinter, A.; Lacour, J.P.; Ferrandiz, C.; Micali, G.; French, L.E.; Lomaga, M.; Dutronc, Y.; Henneges, C.; Wilhelm, S.; Hartz, S.; Paul, C. Journal: British journal of dermatology Issue: Volume 177:Number 4(2017) Page Start: 1014 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Comparison of ixekizumab with ustekinumab in moderate‐to‐severe psoriasis: 24‐week results from IXORA‐S, a phase III study. (1st October 2017) Authors: Reich, K.; Pinter, A.; Lacour, J.P.; Ferrandiz, C.; Micali, G.; French, L.E.; Lomaga, M.; Dutronc, Y.; Henneges, C.; Wilhelm, S.; Hartz, S.; Paul, C. Journal: British journal of dermatology Issue: Volume 177:Number 4(2017) Page Start: 1014 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry. (12th April 2017) Authors: Pérez‐Plaza, A.; Carretero, G.; Ferrandiz, C.; Vanaclocha, F.; Gómez‐García, F.J.; Herrera‐Ceballos, E.; De la Cueva‐Dobao, P.; Belinchón, I.; Sánchez‐Carazo, J.L.; Alsina, M.; López‐Estebaranz, J.L.; Ferrán, M.; Torrado, R.; Carrascosa, J.M.; Llamas‐Velasco, M.; Rivera, R.; Jiménez‐Puya, R.; Gar... Other Names: Ruiz‐Genao Diana investigator.; Mejías Sagrario Galiano investigator.; Mendiola‐Fernández Victoria investigator.; Herrera‐Acosta Enrique investigator.; Muñoz‐Santos Carlos investigator. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 31:Number 6(2017) Page Start: 1021 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). (1st December 2015) Authors: Paul, C.; Cather, J.; Gooderham, M.; Poulin, Y.; Mrowietz, U.; Ferrandiz, C.; Crowley, J.; Hu, C.; Stevens, R.M.; Shah, K.; Day, R.M.; Girolomoni, G.; Gottlieb, A.B. Journal: British journal of dermatology Issue: Volume 173:Number 6(2015:Dec.) Page Start: 1387 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). (7th November 2015) Authors: Paul, C.; Cather, J.; Gooderham, M.; Poulin, Y.; Mrowietz, U.; Ferrandiz, C.; Crowley, J.; Hu, C.; Stevens, R.M.; Shah, K.; Day, R.M.; Girolomoni, G.; Gottlieb, A.B. Journal: British journal of dermatology Issue: Volume 173:Number 6(2015:Dec.) Page Start: 1387 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate–severe psoriasis in Spain. BIOBADADERM registry. (8th November 2012) Authors: Sánchez‐Moya, A.I.; García‐Doval, I.; Carretero, G.; Sánchez‐Carazo, J.; Ferrandiz, C.; Herrera Ceballos, E.; Alsina, M.; Ferrán, M.; López‐Estebaranz, J.‐L.; Gómez‐García, F.; De la Cueva Dobao, P.; Carrascosa, J.‐M.; Vanaclocha, F.; Belinchón, I.; Peral, F.; Dauden, E. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 27:Number 11(2013:Nov.) Page Start: 1366 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. (1st March 2014) Authors: Augustin, M.; Blome, C.; Costanzo, A.; Dauden, E.; Ferrandiz, C.; Girolomoni, G.; Gniadecki, R.; Iversen, L.; Menter, A.; Michaelis‐Wittern, K.; Morita, A.; Nakagawa, H.; Reich, K. Journal: British journal of dermatology Issue: Volume 170:Number 3(2014:Mar.) Page Start: 591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. (March 2014) Authors: Augustin, M.; Blome, C.; Costanzo, A.; Dauden, E.; Ferrandiz, C.; Girolomoni, G.; Gniadecki, R.; Iversen, L.; Menter, A.; Michaelis‐Wittern, K.; Morita, A.; Nakagawa, H.; Reich, K. Journal: British journal of dermatology Issue: Volume 170:Number 3(2014:Mar.) Page Start: 591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Paradoxical eczematous reaction to ixekizumab. (13th August 2018) Authors: Munera‐Campos, M.; Ballesca, F.; Richarz, N.; Ferrandiz, C.; Carrascosa, J.M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 33:Number 1(2019) Page Start: e40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗